• Je něco špatně v tomto záznamu ?

The standardization of cerebrospinal fluid markers and neuropathological diagnoses brings to light the frequent complexity of concomitant pathology in Alzheimer's disease: The next challenge for biochemical markers?

T. Fenouil, A. Fourier, I. Quadrio, N. Streichenberger, S. Bernardini, T. Zima, A. Perret-Liaudet, D. Meyronet,

. 2019 ; 72 (-) : 15-23. [pub] 20190610

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc19044759

During the last two decades, neuropathological examination of the brain has evolved both technically and scientifically. The increasing use of immunohistochemistry to detect protein aggregates paralleled a better understanding of neuroanatomical progression of protein deposition. As a consequence, an international effort was achieved to standardize hyperphosphorylated-Tau (phospho-TAU), ßAmyloid (Aß), alpha syncuclein (alpha-syn), phosphorylated transactive response DNA-binding protein 43 (phospho-TDP43) and vascular pathology detection. Meanwhile harmonized staging systems emerged in order to increase inter rater reproducibility. Therefore, a refined definition of Alzheimer's disease was recommended., a clearer picture of the neuropathological lesions diversity emerged secondarily to the systematic assessment of concomitant pathology highlighting finally a low rate of pure AD pathology. This brings new challenges to laboratory medicine in the field of cerebrospinal fluid (CSF) markers of Alzheimer's disease: how to further validate total Tau, phospho-TAU, Aß40 and Aß42 and new marker level cut-offs while autopsy rates are declining?

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19044759
003      
CZ-PrNML
005      
20200113081258.0
007      
ta
008      
200109s2019 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.clinbiochem.2019.06.004 $2 doi
035    __
$a (PubMed)31194969
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Fenouil, Tanguy $u Institut de Pathologie Est -Neuropathologie, Hospices civils de Lyon, Lyon, France; University Claude Bernard Lyon 1, Lyon, France; Department of Cancer Cell Plasticity, Cancer Research Centre of Lyon, INSERM U1052, CNRS UMR5286, Lyon, France.
245    14
$a The standardization of cerebrospinal fluid markers and neuropathological diagnoses brings to light the frequent complexity of concomitant pathology in Alzheimer's disease: The next challenge for biochemical markers? / $c T. Fenouil, A. Fourier, I. Quadrio, N. Streichenberger, S. Bernardini, T. Zima, A. Perret-Liaudet, D. Meyronet,
520    9_
$a During the last two decades, neuropathological examination of the brain has evolved both technically and scientifically. The increasing use of immunohistochemistry to detect protein aggregates paralleled a better understanding of neuroanatomical progression of protein deposition. As a consequence, an international effort was achieved to standardize hyperphosphorylated-Tau (phospho-TAU), ßAmyloid (Aß), alpha syncuclein (alpha-syn), phosphorylated transactive response DNA-binding protein 43 (phospho-TDP43) and vascular pathology detection. Meanwhile harmonized staging systems emerged in order to increase inter rater reproducibility. Therefore, a refined definition of Alzheimer's disease was recommended., a clearer picture of the neuropathological lesions diversity emerged secondarily to the systematic assessment of concomitant pathology highlighting finally a low rate of pure AD pathology. This brings new challenges to laboratory medicine in the field of cerebrospinal fluid (CSF) markers of Alzheimer's disease: how to further validate total Tau, phospho-TAU, Aß40 and Aß42 and new marker level cut-offs while autopsy rates are declining?
650    _2
$a Alzheimerova nemoc $x mok mozkomíšní $x diagnóza $x patologie $7 D000544
650    _2
$a amyloidní beta-protein $x mok mozkomíšní $x normy $7 D016229
650    _2
$a biologické markery $x mok mozkomíšní $x chemie $7 D015415
650    _2
$a mozek $x patologie $7 D001921
650    _2
$a progrese nemoci $7 D018450
650    _2
$a lidé $7 D006801
650    _2
$a fosforylace $7 D010766
650    _2
$a proteiny tau $x mok mozkomíšní $x chemie $x normy $7 D016875
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Fourier, Anthony $u University Claude Bernard Lyon 1, Lyon, France; Laboratory of Neurobiology, Department of Biochemistry and Molecular Biology, Hospices civils de Lyon, Lyon, France; BioRan Team, Centre de Recherche en Neurosciences de Lyon, CNRS UMR5292, INSERM U1028, France.
700    1_
$a Quadrio, Isabelle $u Laboratory of Neurobiology, Department of Biochemistry and Molecular Biology, Hospices civils de Lyon, Lyon, France.
700    1_
$a Streichenberger, Nathalie $u Institut de Pathologie Est -Neuropathologie, Hospices civils de Lyon, Lyon, France; University Claude Bernard Lyon 1, Lyon, France; Institut Neuro Myogène, CNRS UMR 5310, INSERM U1217, Université Claude Bernard Lyon 1, Lyon, France.
700    1_
$a Bernardini, Sergio $u Laboratory of Clinical Biochemistry, University Hospital Tor Vergata, Roma, Italy.
700    1_
$a Zima, Tomáš $u Institute of Medical Chemistry and Laboratory Medicine, The First Faculty of Medicine and General University Hospital, U Nemocnice 2, CZ-121 08 Prague 2, Czech Republic.
700    1_
$a Perret-Liaudet, Armand $u Laboratory of Neurobiology, Department of Biochemistry and Molecular Biology, Hospices civils de Lyon, Lyon, France.
700    1_
$a Meyronet, David $u Institut de Pathologie Est -Neuropathologie, Hospices civils de Lyon, Lyon, France; University Claude Bernard Lyon 1, Lyon, France; Department of Cancer Cell Plasticity, Cancer Research Centre of Lyon, INSERM U1052, CNRS UMR5286, Lyon, France. Electronic address: david.meyronet@chu-lyon.fr.
773    0_
$w MED00001119 $t Clinical biochemistry $x 1873-2933 $g Roč. 72, č. - (2019), s. 15-23
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31194969 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20200109 $b ABA008
991    __
$a 20200113081630 $b ABA008
999    __
$a ok $b bmc $g 1483028 $s 1083432
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 72 $c - $d 15-23 $e 20190610 $i 1873-2933 $m Clinical biochemistry $n Clin Biochem $x MED00001119
LZP    __
$a Pubmed-20200109

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace